Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.43 |
| ▸ | MERTK | Q12866 | 5/20 | 0.43 |
| ▸ | AXL | P30530 | 4/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408651 | 0.98 | P2RX7 (0.52) | P2RX7PTGESPTGS2HSD11B1MERTK | |
| SCHEMBL6406898 | 0.98 | P2RX7 (0.52) | P2RX7PTGESPTGS2HSD11B1MERTK | |
| SCHEMBL27701237 | 0.78 | KCNA5 (0.53) | P2RX7PTGESPTGS2MERTKAXL | |
| SCHEMBL4969359 | 0.77 | HDAC4 (0.51) | HSD11B1ALDH1A1HDAC4 | |
| SCHEMBL4974153 | 0.77 | HDAC4 (0.51) | HSD11B1ALDH1A1HDAC4 | |
| SCHEMBL4974151 | 0.77 | HDAC4 (0.51) | HSD11B1ALDH1A1HDAC4 | |
| SCHEMBL6406684 | 0.77 | HDAC4 (0.51) | HSD11B1ALDH1A1HDAC4 | |
| SCHEMBL3144414 | 0.77 | PTGES (0.46) | P2RX7PTGESPTGS2MERTKAXL | |
| SCHEMBL2064031 | 0.75 | KCNA5 (0.51) | P2RX7MERTKAXLKCNA5ALDH1A1 | |
| SCHEMBL6406617 | 0.75 | HDAC4 (0.52) | HSD11B1ALDH1A1SMN1; SMN2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | P2RX7 2799/4885PTGES 424/4885PTGS2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.